Vaccination is the mainstream measure against coronavirus disease 2019(COVID-19).As of May 2022,more than 80%of the Japanese population has received vaccination doses(1),and booster vaccination programs are in progres...Vaccination is the mainstream measure against coronavirus disease 2019(COVID-19).As of May 2022,more than 80%of the Japanese population has received vaccination doses(1),and booster vaccination programs are in progress.Acute disseminated encephalomyelitis is the most common type of demyelination following vaccinations,and although an increase in neuromyelitis optica spectrum disease(NMOSD)has recently been reported worldwide(2-4),no collective data,especially after newly developed mRNA vaccines against COVID-19,have been reported yet.展开更多
Introduction SARS-CoV-2 vaccination is an effective means to prevent severe illness and death due to SARS-CoV-2 infection[1].Vaccine safety has been carefully monitored to be sure that the benefit outweighs the risk o...Introduction SARS-CoV-2 vaccination is an effective means to prevent severe illness and death due to SARS-CoV-2 infection[1].Vaccine safety has been carefully monitored to be sure that the benefit outweighs the risk of adverse events(AEs).Common AEs of the BNT162b2 mRNA vaccine,for example,include fatigue(45%),headache(40%),and chills(28%)after the first administration in accordance with the adult phase Ⅲ clinical trial[1].展开更多
文摘Vaccination is the mainstream measure against coronavirus disease 2019(COVID-19).As of May 2022,more than 80%of the Japanese population has received vaccination doses(1),and booster vaccination programs are in progress.Acute disseminated encephalomyelitis is the most common type of demyelination following vaccinations,and although an increase in neuromyelitis optica spectrum disease(NMOSD)has recently been reported worldwide(2-4),no collective data,especially after newly developed mRNA vaccines against COVID-19,have been reported yet.
基金supported in part by a grant of the collaborative studies for radiation disasters and medical science in the Fukushima Medical University(Fukushima,Japan)the internal fund of the Soma Central Hospital(Soma,Fukushima,Japan)the Medical Governance Research Institute(Minato-ward,Tokyo,Japan).
文摘Introduction SARS-CoV-2 vaccination is an effective means to prevent severe illness and death due to SARS-CoV-2 infection[1].Vaccine safety has been carefully monitored to be sure that the benefit outweighs the risk of adverse events(AEs).Common AEs of the BNT162b2 mRNA vaccine,for example,include fatigue(45%),headache(40%),and chills(28%)after the first administration in accordance with the adult phase Ⅲ clinical trial[1].
